Phase 3 N=3,506 Myocardial Ischemia and Transfusion
Myocardial Infarction · Anemia
Primary: Number of Participants With All-cause Mortality or Nonfatal Myocardial Reinfarction — 255; 295 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=14 Acupressure in Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Feasibility of Self-performed Acupressure in Patients With Rheumatoid Arthritis Assessed by the Number of Sessions Completed — 6 Participants
Phase 4 N=101 A Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10)
Squamous Cell Carcinoma of Head and Neck
Primary: Objective Response Rate (ORR) — 48.5 Percentage of Participants
N/A N=15 Brain Stimulation and Cognitive Training - Efficacy
Schizophrenia · Schizo Affective Disorder · Bipolar Disorder
Primary: Change in Working Memory Performance - Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB)…
Phase 1 N=14 A Study to Evaluate Molnupiravir (MK-4482) in Participants With Moderate Hepatic Impairment (MK-4482-016)
Hepatic Impairment
Primary: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-∞) of Plasma N-Hydroxycitidine (NHC) — 8930; 10900 hr*ng/mL
Phase 2 N=29 Eribulin and Lenvatinib in Advanced Solid Tumors
Cancer · Solid Tumor
Primary: Overall Response Rate of Lenvatinib and Eribulin (Phase II) — 7; 13; 3 participants
N/A N=24 To Compare Different Soft Tissue Grafts at the Time of Lateral Ridge Augmentation Procedure.
Bone Graft; Complications, Infection or Inflammation · Ridge Deficency · Dental Implant
Primary: Measure Changes Clinically in Crestal Soft Tissue Thickness (in mm) — 1.96; 1.59; 0.33 mm
N/A N=1,623 COVID-19: Healthy Oregon (Oregon Saludable): Together We Can (Juntos Podemos)
Health Behavior · Health Care Utilization
Primary: COVID-19 Prevention Health Behaviors 1 — 6.0; 6.7; 4.8 score on a scale — p=.26
N/A N=2,153 Reaching 90 90 90 in Adolescents in Zambia: Using All Our SKILLZ
HIV Infections · Pregnancy Related · STI
Primary: Number of Participants Undergoing HIV Testing Within 12 Months — 361; 552 Participants
Phase 3 N=298 A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical Trial
Growth Hormone Deficiency, Pediatric · Endocrine System Diseases · Hormone Deficiency
Primary: Number of Subjects With Treatment-Emergent Adverse Events [Long-Term Safety and Tolerability] — 226 Participants
Phase 3 N=362 Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines
Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)
Primary: Main Period: Percentage of Glabellar Frown Line (GFL) Responders at Day 30 — 0; 52.3 percentage of subjects — p=<0.0001
Phase 3 N=220 Effectiveness of Higher Aspirin Dosing for Prevention of Preeclampsia in High Risk Obese Gravida
Pre-Eclampsia · Hypertension in Pregnancy · Obesity
Primary: Number of Participants With Preeclampsia Diagnosis With Severe Features Based on Clinician Diagnosis — 37; 41 Participants
N/A N=86 LiquID Guide Catheter Extension Safety Study
Coronary Artery Disease
Primary: The Number of Participants With In-hospital Major Adverse Cardiac Events (MACE) — 2 Participants
Phase 4 N=32 Effects of Prescription Omega-3 on LDL-C in Primary Hypercholesterolemia
Primary Hypercholesterolemia
Primary: Percent Change From Baseline in LDL-C During Each Treatment — 3.4; -0.7 Percent change from baseline
Phase 3 N=510 A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy
Cystic Fibrosis
Primary: Treatment Period: Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 504…